Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib

B. Melosky, P. Cheema, G. Liu

Abstract


-

Keywords


Non-small cell lung cancer, NSCLC, Anaplastic lymphoma kinase, ALK, Tyrosine Kinase Inhibitor, TKI, CNS, metastases

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.26.4809






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)